Revance Therapeutics | RVNC - Ordinary Share Capital


Revance Therapeutics reported $105K in Ordinary Share Capital for its fiscal quarter ending in June of 2024.



Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
ALKERMES USD 165.61M 503K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Cara Therapeutics USD 9.38M 9.38M Sep/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
J&J USD 2.41B 584K Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
P&G USD 2.34B 1.67B Dec/2025
Pacira USD 41.12M 1.85M Dec/2025
Supernus Pharmaceuticals USD 57.12M 1000K Sep/2025